TY - JOUR
T1 - Changing the way we do business
T2 - Recommendations to accelerate biomarker development in pancreatic cancer
AU - Tempero, Margaret A.
AU - Klimstra, David
AU - Berlin, Jordan
AU - Hollingsworth, Tony
AU - Kim, Paula
AU - Merchant, Nipun
AU - Moore, Malcolm
AU - Pleskow, Doug
AU - Wang-Gillam, Andrea
AU - Lowy, Andrew M.
PY - 2013/2/1
Y1 - 2013/2/1
N2 - Pancreatic ductal adenocarcinoma is the most aggressive of all epithelial malignancies. In contrast to the favorable trends seen in most other common malignancies, the five-year survival of patients with this disease remains only 6%, a statistic that has changed minimally for decades. Only two drugs have been approved by the U.S. Food and Drug Administration (FDA) for use in pancreatic cancer in the last 15 years, and there are no established strategies for early detection.
AB - Pancreatic ductal adenocarcinoma is the most aggressive of all epithelial malignancies. In contrast to the favorable trends seen in most other common malignancies, the five-year survival of patients with this disease remains only 6%, a statistic that has changed minimally for decades. Only two drugs have been approved by the U.S. Food and Drug Administration (FDA) for use in pancreatic cancer in the last 15 years, and there are no established strategies for early detection.
UR - http://www.scopus.com/inward/record.url?scp=84873361771&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-12-2745
DO - 10.1158/1078-0432.CCR-12-2745
M3 - Review article
C2 - 23344262
AN - SCOPUS:84873361771
SN - 1078-0432
VL - 19
SP - 538
EP - 540
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 3
ER -